Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Spruce Biosciences, Inc. SPRB

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.00
Total sells
0.00
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy 1 — — — — — — — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
165.68
Revenue
4.91
Net Income
(51.35)
Free Cash Flow
(42.78)
Net Debt
(89.20)
Current Ratio
9.23
Debt/Equity
0.08
P/E ratio
0.00
P/S ratio
26.66
P/B ratio
1.56
Past 5Y EPS Growth
(16.93%)
This Y EPS Growth
49.35%
Next Y EPS Growth
103.48%
Next 5Y EPS Growth
41.25%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 96.34 38.75 48.91 96.30
Receivables — — — —
Inventory — — — —
Other 1.97 2.28 2.85 0.23
102.18 44.21 52.11 101.15
2023 2024 2025 Q'26
Payables 3.33 1.30 0.94 1.21
ST’ Debt 1.62 1.62 — 2.50
Other — — — —
24.47 15.25 10.09 10.96
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’24 2.00 1.61 0.60 0.70
4.91
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (8.73) (22.12) — —
—
’25 (12.73) (8.83) (5.32) (6.46)
(33.33)
’24 (14.96) (11.11) (9.22) (20.68)
(55.96)
’23 (11.79) 1.99 (12.27) (11.21)
(33.27)
’22 (11.83) (9.54) (8.58) (11.74)
(41.68)
’21 (8.79) (9.69) (7.60) (9.80)
(35.88)
’20 (5.96) (4.70) (7.60) (9.27)
(27.52)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (8.74) (22.25) — —
—
’25 (12.73) (8.83) (5.32) (6.46)
(33.33)
’24 (14.96) (11.11) (9.22) (20.68)
(55.96)
’23 (11.79) 1.99 (12.28) (11.21)
(33.28)
’22 (11.83) (9.55) (8.58) (11.74)
(41.69)
’21 (8.81) (9.70) (7.66) (9.80)
(35.97)
’20 (5.96) (4.71) (7.64) (9.29)
(27.59)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (8.94) (6.68) — —
—
’25 (24.06) (3.50) (14.58) (9.58)
(50.83)
’24 (21.05) (16.54) (15.79) (42.86)
(96.99)
’23 (30.07) (24.06) (22.56) (17.29)
(93.23)
’22 (37.59) (38.35) (36.09) (35.34)
(147.37)
’21 (31.58) (37.59) (36.84) (29.32)
(136.09)
’20 (0.22) — (928.57) (29.32)
(370.68)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 5,371.88 5,681.25 2,053.13 7.00 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 26,381.25 20,081.25 33,468.75 2,508.75 — — —
High Price
— — — — ‡‡‡‡ ‡‡‡‡ 27 29 21 8 — — —
Employees
— — — — ‡‡‡ ‡‡‡ 0.00 0.35 0.23 0.00 — — —
Revenue/Emp
— — — — — — — 10.09 4.91 — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 100.00% 100.00% — — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (46.18) (47.92) (53.04) (38.97) — — —
EBT
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% (474.96%) (1,079.94%) 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (46.18) (47.92) (53.04) (38.97) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.09 (0.57) 0.05 0.02 — — —
Depreciation
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 19.70 8.93 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (147.37) (93.23) (96.99) (50.83) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (133.22) (64.96) (101.75) (43.45) — — —
Cash Flow/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.03) (0.01) 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (133.24) (64.98) (101.75) (43.45) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 218.88 149.37 52.40 55.43 — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.31 0.51 0.55 0.77 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — 0.00 0.00 — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
— — — — — — — 845.29 264.58 — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — 111.47 45.08 — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — 836.07 257.05 — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — — — — (253.43) (22.55) — — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.68) (33.27) (55.96) (33.33) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) (0.01) — — — — —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.69) (33.28) (55.96) (33.33) — — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 71.16 77.72 28.96 42.03 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.92 3.34 1.75 — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (74.16) (93.00) (37.01) (48.91) — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 68.49 76.51 28.82 42.52 — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (43.54%) (50.55%) (71.12%) (79.34%) — — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (51.35%) (66.10%) (100.70%) (109.24%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Spruce Biosciences (SPRB), a lean clinical-stage biotech targeting rare endocrine disorders like congenital adrenal hyperplasia (CAH), has endured a volatile path since its 2020 IPO, marked by COVID trial delays, Phase 2 hype, and recent Phase 3 DIAMOND-1 success showing glucocorticoid reductions with its lead cortisol modulator, tildacerfont. Despite heavy R&D burn—EPS plummeting to -$147 in 2022 and shares diluting 75%—2023 brought first revenue of $10.1 million at perfect gross margins, though 2024 saw a dip amid trial wind-downs, eroding book value and inflating valuations like PS at 264x.

Analysts remain exuberantly bullish, forecasting 141-327% upside from recent levels, driven by H2 2025 FDA filing potential unlocking $1B+ peak sales in a underserved 50,000-patient U.S. market, with revenue projected to surge 722% to $40.3 million in 2025 and EPS losses narrowing 78%. Low debt, cash buffers, and nimble operations under steady leadership position SPRB as a high-beta underdog versus peers like Neurocrine, trading at a discount on forward EV/sales—yet binary risks like pending DIAMOND-2 data and post-approval cliffs loom large in this rare disease gold rush.

Read full commentary →

Spruce Biosciences, Inc. (SPRB) Latest News

News by impact score

Fine-tune

27 Aug

3 investorshub.advfn.com, 8:09 AM
Spruce Biosciences stock rose after an analyst endorsed the company's regulatory progress. Analyst support for regulatory progress triggered short-term stock gains and may influence sentiment around future approvals.

24 Aug

4 , 8:00 AM
Spruce Biosciences completed positive pre-BLA meetings with the FDA and confirmed its BLA submission for TA-ERT remains on track for Q4 2026. Positive FDA pre-BLA meetings and confirmed Q4 2026 BLA timeline advance TA-ERT toward potential approval and commercial launch.

12 Aug

4 , 8:00 AM
Cure Sanfilippo Foundation and National MPS Society invested $5.5 million in Spruce Biosciences, Inc. (SPRB). Strategic $5.5 million investment supplies capital that advances Spruce Biosciences' core development programs and strengthens its market position.

8 Jun

3 Business Wire, 4:05 PM
Spruce Biosciences announced presentation of long-term tralesinidase alfa enzyme replacement therapy data in Sanfilippo Syndrome Type B at the 18th International MPS Symposium. Long-term therapy data presentation at symposium may moderately influence market perception of pipeline progress.

13 May

3 Business Wire, 8:00 AM
Spruce Biosciences (SPRB) reported first quarter 2026 financial results and provided corporate updates. Quarterly financial results and corporate updates moderately influence financial performance and investor sentiment.

20 Apr

4 , 11:45 PM
Spruce Biosciences, Inc. (SPRB) priced an underwritten public offering of 25 million shares of common stock or pre-funded warrants at $0.80 per share, expecting gross proceeds of approximately $20 million before expenses. Public offering pricing raises crucial capital for clinical development but introduces significant share dilution, likely pressuring stock price and altering financial trajectory.

3 , 4:01 PM
Spruce Biosciences, Inc. (SPRB) announced a proposed public offering of common stock and pre-funded warrants. Public offering provides capital for operations but dilutes existing shareholders, leading to moderate impact on financial performance and market sentiment.

3 Apr

3 Zacks, 9:55 AM
Wall Street analysts forecast a 181.21% rally for Spruce Biosciences (SPRB) stock and detail trading strategies to capitalize on the upside. Analysts' 181.21% upside target for SPRB signals moderately positive market sentiment with potential short-term price influence.

18 Mar

4 Zacks, 9:55 AM
Wall Street analysts expect Spruce Biosciences (SPRB) stock to rally 208.32%, highlighting strong upside potential based on their consensus price target. Analyst consensus projects 208.32% upside for SPRB, likely shifting investor sentiment and stock trajectory significantly.

17 Mar

4 Insider Monkey, 7:59 PM
Spruce Biosciences (SPRB) appointed Dale Hooks as Chief Commercial Officer and reported a narrowed net loss of $39 million for 2025. Appointing a CCO positions the company for commercialization while narrowing net loss indicates improving financial trajectory.

9 Mar

4 Business Wire, 7:05 AM
Spruce Biosciences, Inc. (SPRB) reported full year 2025 financial results and provided corporate updates. Full year financial results combined with corporate updates signal major strategic and operational developments impacting future performance and investor sentiment.

4 Business Wire, 7:00 AM
Spruce Biosciences appoints Dale Hooks, an accomplished rare disease commercial leader with prior roles at Sarepta, Ultragenyx, and BioMarin, as Chief Commercial Officer to lead commercialization efforts for its pipeline including tildacerfont for congenital adrenal hyperplasia. Appointing an experienced rare disease commercialization expert as CCO advances strategic readiness for pipeline launches and enhances market positioning.

3 Mar

5 Insider Monkey, 10:20 AM
Spruce Biosciences (SPRB) gains FDA support for accelerated approval pathway. FDA support for accelerated approval pathway is a game-changing regulatory milestone that could fast-track commercialization and redefine SPRB's competitive position.

1 Mar

4 www.marketbeat.com, 5:37 PM
Spruce Biosciences presented positive MPS IIIB clinical data and targets Q4 BLA submission at the Oppenheimer Conference. Positive MPS IIIB data and imminent Q4 BLA submission mark a critical regulatory milestone boosting SPRB's path to potential approval and market value.

18 Feb

4 Business Wire, 7:00 AM
Spruce Biosciences announced positive Type B meetings with the U.S. FDA for TA-ERT, its enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), supporting advancement to a registrational trial. Positive FDA Type B meetings clear path for registrational trial of TA-ERT in rare disease MPS IIIB, significantly advancing Spruce Biosciences' lead pipeline and enhancing market prospects.

5 Feb

4 Business Wire, 4:05 PM
Long-term data presented at the 22nd Annual WORLDSymposium™ indicates that Tralesinidase Alfa, an enzyme replacement therapy developed by Spruce Biosciences, has the potential to be the first disease-modifying treatment for Sanfilippo Syndrome Type B (MPS IIIB). The findings suggest significant therapeutic benefits, highlighting the drug's role in altering the disease's progression. The presentation of long-term data on a potential first-in-class treatment for a rare disease could significantly influence Spruce Biosciences' market position and investor sentiment.

3 Feb

4 Business Wire, 8:00 AM
Spruce Biosciences, Inc. has strengthened its leadership team by adding key personnel with extensive regulatory and clinical development experience. This move aims to enhance the company's capabilities in advancing its product pipeline and navigating the complexities of regulatory environments, ultimately positioning Spruce for future growth and success in the biopharmaceutical sector. The addition of experienced leaders is likely to significantly impact Spruce's strategic direction and operational effectiveness.

28 Jan

3 Business Wire, 8:00 AM
Spruce Biosciences, Inc. announced data presentations at the 22nd Annual WORLDSymposium™, highlighting advancements in their research and development efforts. The presentations focus on the company's ongoing work in rare diseases, particularly in the context of their therapeutic candidates. This event serves as a platform for Spruce to showcase its commitment to innovation and collaboration within the scientific community. The data presentations may enhance Spruce's visibility and credibility in the rare disease sector, potentially influencing future partnerships and funding opportunities.

18 Jan

4 PR Newswire, 7:02 PM
Harbour BioMed has acquired common stock in Spruce Biosciences, Inc., enhancing their strategic collaboration. This investment aims to bolster the development of Spruce's therapies, particularly in the field of rare diseases. The partnership is expected to leverage Harbour BioMed's resources and expertise to accelerate Spruce's growth and innovation in biopharmaceuticals. The acquisition signifies a major strategic move that could significantly enhance Spruce's development capabilities and market position.

8 Jan

4 Business Wire, 8:00 AM
Spruce Biosciences, Inc. has secured up to $50 million in growth capital from Avenue Capital, aimed at advancing its clinical programs and expanding its operations. This funding will support the company's initiatives in developing treatments for rare endocrine disorders, enhancing its financial position and strategic capabilities. Securing significant growth capital is likely to enable major strategic moves and enhance product development, impacting the company's future trajectory.

24 Dec

4 TipRanksSimply Wall St.South Florida Sun SentinelSimply Wall St.MT NewswiresSourcing JournalMT NewswiresMT Newswires, 6:30 AM
Oppenheimer has initiated coverage of Spruce Biosciences, Inc. (SPRB) with an 'Outperform' rating, indicating a positive outlook for the company's future performance. This initiation suggests confidence in Spruce's potential growth and market position, likely driven by its innovative approaches in the biosciences sector. The initiation of coverage with an 'Outperform' rating signals significant investor interest and potential for growth in Spruce Biosciences.

23 Dec

3 The Fly, 9:33 AM
Spruce Biosciences, Inc. (SPRB) has been initiated by Wall Street analysts, indicating a new interest in the company's stock. This comes alongside a downgrade for Coty, highlighting a shift in analyst sentiment within the market. The initiation of coverage on Spruce suggests potential growth or developments that analysts find noteworthy. Analyst initiation may influence market sentiment and interest in Spruce Biosciences, but the overall impact on its trajectory remains limited.

15 Dec

3 Business Wire, 8:00 AM
Spruce Biosciences, Inc. has appointed Keli Walbert, a seasoned pharmaceutical commercial leader, to its Board of Directors. Walbert brings extensive experience in the biopharmaceutical industry, having held leadership roles at various companies. Her expertise is expected to enhance Spruce's strategic direction and commercial capabilities as the company focuses on advancing its product pipeline. The appointment of a proven leader may positively influence Spruce's strategic direction and operational effectiveness.

10 Nov

3 Business Wire, 4:05 PM
Spruce Biosciences, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and corporate updates. The company continues to focus on its pipeline and strategic initiatives aimed at enhancing its market position. Financial performance showed trends that may influence future operations and investor sentiment. The financial results and corporate updates indicate a moderately noticeable influence on the company's future performance and market positioning.

15 Oct

4 ZacksZacksZacksZacksZacksZacksZacksZacks, 12:00 PM
Spruce Biosciences, Inc. (SPRB) is highlighted as a strong momentum stock due to its recent performance and strategic initiatives. The company is focused on developing treatments for rare endocrine disorders, which positions it favorably in a niche market. Analysts suggest that the stock's upward trend may continue, driven by positive clinical trial results and potential partnerships. Investors are encouraged to consider SPRB as a viable option for growth in their portfolios. Positive clinical trial results and potential partnerships could significantly enhance the company's market position and investor sentiment.

8 Oct

4 Business Wire, 8:00 AM
Spruce Biosciences, Inc. has announced a private placement financing round, raising $50.0 million. The funds will be used to support the company's ongoing clinical development programs and general corporate purposes. This financing is expected to enhance Spruce's financial position and facilitate the advancement of its product pipeline. The $50 million financing is a significant strategic move that will bolster the company's clinical development efforts and overall market position.

7 Oct

4 Barrons.com, 9:44 AM
Spruce Biosciences, Inc. (SPRB) experienced a remarkable 1,400% surge in stock price, driven by investor optimism surrounding its rare-disease drug. The company's promising developments in treatments for conditions like congenital adrenal hyperplasia have attracted significant attention, leading to increased market interest and speculation about future growth. Analysts are closely monitoring the company's progress and potential regulatory approvals, which could further influence its market position. The substantial stock price increase reflects significant investor confidence in the company's rare-disease drug developments, which could alter its market trajectory.

6 Oct

4 Investor's Business Daily, 4:04 PM
Spruce Biosciences, Inc. (SPRB) experienced a dramatic surge in stock price, skyrocketing over 1,600% due to positive developments regarding its drug candidate for treating congenital adrenal hyperplasia (CAH). The company announced promising clinical trial results, which significantly boosted investor confidence and market interest. This surge reflects heightened optimism about the potential for the drug to address unmet medical needs in the CAH patient population, leading to increased trading volume and market capitalization. The significant rise in stock price is driven by promising clinical trial results that could alter the company's market position and investor sentiment.

4 Business Wire, 8:00 AM
Spruce Biosciences, Inc. has received Breakthrough Therapy Designation from the U.S. FDA for its enzyme replacement therapy, Tralesinidase Alfa (TA-ERT), aimed at treating Sanfilippo Syndrome Type B (MPS IIIB). This designation is intended to expedite the development and review process for therapies that demonstrate significant potential in treating serious conditions. The company aims to address the unmet medical needs of patients with this rare genetic disorder. Breakthrough Therapy Designation is likely to significantly enhance the development timeline and market potential for Tralesinidase Alfa.

15 Sep

3 Business Wire, 7:00 AM
Spruce Biosciences, Inc. has resumed trading on the Nasdaq Capital Market after a temporary halt. The company is focused on developing therapies for rare endocrine disorders and aims to enhance its market presence following the trading resumption. Resuming trading may positively influence market sentiment and operational aspects but is not expected to fundamentally alter the company's trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us